Trillium Therapeutics acquires Australia’s Arthron

Trillium Therapeutics Inc, Toronto, has acquired Arthron Ltd Pty, a subsidiary of Prima Biomed Ltd, Melbourne Australia. Trillium will provide Prima with an upfront cash payment and shares representing 5.6% of its outstanding share capital. Prima will also be eligible to receive additional shares if certain business development and clinical milestones are met. Arthron owns or controls intellectual property relating to its activating receptor FcyRIIa, which holds potential for treatment of autoimmune disease such as rheumatoid arthritis and lupus. The assets will complement Trillium’s expertise in immunology and opens up a new line of collaboration with the Austin Research Institute, a Melbourne-based institute that has close ties to Arthron....